切换至 "中华医学电子期刊资源库"
高级检索
中华介入放射学电子杂志

中华介入放射学电子杂志 ›› 2016, Vol. 04 ›› Issue (02) : 71 -76. doi: 10.3877/cma.j.issn.2095-5782.2016.02.004

所属专题： 文献；

非血管介入

PVA-TACE治疗肝细胞癌并肝肺分流的临床疗效及预后分析
刘秋松1, 张恭良2, 梅雀林3, 李彦豪3,†()   
  1. 1. 361004　福建厦门，厦门大学附属中山医院肿瘤与血管介入科
    2. 510515　广东广州，南方医科大学南方医院放射科
    3. 510515　广东广州，南方医科大学南方医院介入科
  • 收稿日期:2016-03-10 出版日期:2016-05-01
  • 通信作者: 李彦豪

Polyvinyl alcohol chemoembolization for hepatocellular carcinoma with hepatopulmonary shunting: clinical efficacy and prognostic factors

Qiusong Liu1, Gongliang Zhang2, Quelin Mei3, Yanhao Li3,†()   

  1. 1. Department of Interventional Radiology, Affiliated Zhongshan Hospital, Xiamen University, Xiamen 361004, China
    2. Department of Radiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
    3. Department of Interventional Radiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
  • Received:2016-03-10 Published:2016-05-01
  • Corresponding author: Yanhao Li
  • About author:
    Corresponding author: Li Yanhao, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

刘秋松, 张恭良, 梅雀林, 李彦豪. PVA-TACE治疗肝细胞癌并肝肺分流的临床疗效及预后分析[J/OL]. 中华介入放射学电子杂志, 2016, 04(02): 71-76.

Qiusong Liu, Gongliang Zhang, Quelin Mei, Yanhao Li. Polyvinyl alcohol chemoembolization for hepatocellular carcinoma with hepatopulmonary shunting: clinical efficacy and prognostic factors[J/OL]. Chinese Journal of Interventional Radiology(Electronic Edition), 2016, 04(02): 71-76.

目的：

评价聚乙烯醇微粒肝动脉化疗栓塞（PVA-TACE）治疗肝细胞癌（HCC）并肝肺分流（HPS）的临床疗效，分析影响生存预后的因素。

方法：

回顾性分析42例HCC并HPS患者资料，依据分流途径分为门静脉-腔静脉分流组（A组，9例）与肝动脉-肝静脉分流组（B组，33例）。依据分流速度采用不同规格聚乙烯醇（PVA）微粒进行肝动脉化疗栓塞（TACE）治疗，随访并分析生存期及术后并发症。采用Kaplan-Meier法计算累积生存率，采用Cox模型分析生存预后的影响因素。

结果：

42例患者中位生存期（OS）为9.5个月，6、12个月生存率分别为74.9%、39.4%。A组与B组中位OS分别为10.5个月、9.5个月，两组生存期无明显差异（χ2=0.410，P=0.522）。Cox回归分析结果显示：行为状态（PS）评分较高（HR=2.454，P=0.026）、肿瘤负荷>50%（HR=3.477，P=0.019）及门静脉主干癌栓形成（P=0.006）为预后的独立危险因素，而多次栓塞（HR=0.329，P=0.008）为预后的独立保护因素。

结论：

经谨慎选择病例，PVA-TACE治疗HCC合并HPS安全、有效。经多次栓塞治疗患者预后较好，而PS评分较高、肿瘤负荷较大及门静脉主干癌栓形成的患者预后不良。

关键词: 聚乙烯醇, 癌，肝细胞, 肝肺分流, 疗效, 预后分析
Objective:

To evaluate the efficacy and prognosis of polyvinyl alcohol (PVA) chemoembolization in treating hepatocellular carcinoma (HCC) with hepatopulmonary shunting (HPS).

Methods:

A total of 42 patients' clinical data were retrospectively analyzed. According to the shunting pathway, the patients were divided into group A (portal-systemic shunting, n=9) and group B (arterio-hepatic vein shunting, n=33). Based on shunting speed, different amount of PVA was used to embolize the shunts. The overall survival (OS) and postoperative complications, etc. were analyzed in the follow-up study. Survival prognostic factors were assessed by univariate Kaplan-Meier analysis with Log-rank test and a multivariate Cox proportional hazard model.

Results:

The median OS of the 42 patients was 9.5 months, and the 6-month, 12-month survival rate were 74.9% and 39.4%, respectively. The median OS of the group A and group B were 10.5 months and 9.5 months, respectively, showing no significant difference between two groups (χ2=0.410, P=0.522). Cox multivariate survival analysis revealed that higher performance status (PS) score (HR=2.454, P=0.026), tumor burden >50% (HR=3.477, P=0.019) and main portal vein invasion (P=0.006) were independent risk factors. Multiple embolization (HR=0.329, P=0.008) was an independent protection factor.

Conclusion:

PVA chemoembolization is a safe and effective strategy for selected HCC patients with HPS . Multiple embolization can achieve better survival prognosis in HCC with HPS patients while for those with, tumor burden >50% and main portal vein invasion it showed poor survival prognosis.

Key words: Polyvinyl alcohol, Carcinoma, hepatocellular, Hepatopulmonary shunting, Treatment outcome, Prognosis
表1 42例肝细胞癌合并肝肺分流患者的基线情况
参数 门静脉-腔静脉分流组（9例） 肝动脉-肝静脉分流组（33例） χ2值 P值
分流速度类型 ? ? ? ?
? 快速型 9 8 13.526 <0.001
? 中速型 0 11 ? ?
? 慢速型 0 14 ? ?
肿瘤边界 ? ? ? ?
? 局限型 4 29 7.735 0.005
? 浸润型 5 4 ? ?
肿瘤负荷 ? ? ? ?
? ≤50% 7 18 1.546 0.214
? >50% 2 15 ? ?
BCLC分期a ? ? ? ?
? B 2 7 0.004 0.948
? C 7 26 ? ?
AFP (μg/L) ? ? ? ?
? <400 3 15 0.414 0.520
? ≥400 6 18 ? ?
门静脉癌栓 ? ? ? ?
? 主干 5 5 1.423 0.233
? 一级分支 0 12 ? ?
? 无 4 16 ? ?
肝静脉癌栓 ? ? ? ?
? 有 0 13 5.013 0.025
? 无 9 20 ? ?
图1 巨块型肝癌并下腔静脉癌栓形成、中速型肝动脉-肝静脉分流，因急性肺动脉栓塞急诊入院。急诊行下腔静脉支架及肺动脉支架置入术，后续行多次PVA-TACE治疗。
图2 团块型肝癌并肝静脉-下腔静脉分流、右心房癌栓形成
图3 肝动脉-门静脉分流与肝动脉-肝静脉分流
表2 Cox回归分析肝细胞癌合并肝肺分流患者预后的影响因素
因素 β SE Waldχ2 df P HR（95%CI）
肿瘤负荷 1.246 0.530 5.529 1 0.019 3.477（1.231～9.826）
PS评分a 0.898 0.404 4.942 1 0.026 2.454（1.112～5.416）
多次栓塞治疗 -1.112 0.421 6.968 1 0.008 0.329（0.144～0.751）
门静脉癌栓 ? ? 10.166 2 0.006 ?
无:主干 -1.605 0.599 7.190 1 0.007 0.201（0.062～0.649）
一级分支:主干 -1.459 0.534 7.457 1 0.006 0.232（0.082～0.662）
1
Ward TJ, Tamrazi A, Lam MG, et al. Management of high hepatopulmonary shunting in patients undergoing hepatic radioembolization[J]. J Vasc Interv Radiol，2015 ，26(12):1751-1760. doi: 10.1016/j.jvir.2015.08.027.
2
刘秋松, 梅雀林, 李彦豪, 等. 聚乙烯醇微粒末梢性化疗栓塞肝细胞癌合并肝动静脉分流的疗效与安全性[J]. 中华放射学杂志, 2015, 49(10): 763-768. doi:10.3760/cma.j.issn.1005-1201.2015.10.010.
3
Mei Q, Li Y. Transcatheter arterial embolization of hepatic arteriovenous shunts in patients with hepatocellular carcinoma[J]. Semin Intervent Radiol，2012，29(3):237-240. doi: 10.1055/s-0032-1326935.
4
Wu JJ, Chao M, Zhang GQ，et al. Pulmonary and cerebral lipiodol embolism after transcatheter arterial hemoembolization in hepatocellular carcinoma[J]. World J Gastroenterol, 2009,15(5):633-635.
5
Kim JT, Heo SH, Choi SM, et al. Cerebral embolism of iodized oil (lipiodol) after transcatheter arterial chemoembolization for hepatocellular carcinoma[J]. J Neuroimaging,2009,19(4):394-397. doi: 10.1111/j.1552-6569.2009.00380.x.
6
Vogl TJ, Nour-Eldin NE, Emad-Eldin S,et al. Portal vein thrombosis and arterioportal shunts: effects on tumor response after chemoembolization of hepatocellular carcinoma[J]. World J Gastroenterol, 2011，17(10):1267-1275. doi: 10.3748/wjg.v17.i10.1267.
7
Chung SM, Yoon CJ, Lee SS,et al. Treatment outcomes of transcatheter arterial chemoembolization for hepatocellular carcinoma that invades hepatic vein or inferior vena cava[J]. Cardiovasc Intervent Radiol，2014，37(6):1507-1515. doi: 10.1007/s00270-014-0841-1.
8
Jun CH, Sim DW, Kim SH, et al. Risk factors for patients with stage IVB hepatocellular carcinoma and extension into the heart: prognostic and therapeutic implications[J]. Yonsei Med J，2014，55(2):379-386. doi: 10.3349/ymj.2014.55.2.379.
9
Chern MC, Chuang VP, Cheng T, et al. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with inferior vena cava and right atrial tumors[J]. Cardiovasc Intervent Radiol，2008，31(4):735-744. doi: 10.1007/s00270-008-9342-4.
10
Chun YH, Ahn SH, Park JY, et al. Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava/heart invasion[J]. Anticancer Res, 2011, 31(12): 4641-4646.
11
Koo JE, Kim JH, Lim YS, et al. Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus[J]. Int J Radiat Oncol Biol Phys, 2010, 78(1): 180-187. doi: 10.1016/j.ijrobp.2009.07.1730.
12
张欣，钱坤，郑传胜 . TACE治疗原发性肝癌——循证医学证据分析[J/CD] .中华介入放射学电子杂志,2015, 3(2): 100-103. doi: 10.3877/cma.j.issn.2095-5782.2015.02.012.
13
Chern MC, Chuang VP, Liang CT，et al. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion: safety, efficacy, and prognostic factors[J]. J Vasc Interv Radiol，2014, 25(1): 32-40. doi: 10.1016/j.jvir.2013.10.013.
14
欧阳墉, 欧阳雪晖. 肝内肝动脉-门静脉分流的研究进展[J]. 医学影像学杂志, 2005, 15(12): 1019-1023. doi:10.3969/j.issn.1006-9011.2005.12.001.
15
孙磊, 施海彬, 刘圣, 等. 肝细胞癌肝动脉门静脉分流形成的相关因素分析[J]. 介入放射学杂志, 2012, 21(3): 206-210. doi:10.3969/j.issn.1008-794X.2012.03.008.
16
Hu HT, Kim JH, Lee LS, et al. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort[J]. J Vasc Interv Radiol, 2011, 22(7): 917-923. doi: 10.1016/j.jvir.2011.03.005.
17
Jia L, Kiryu S, Watadani T, et al. Prognosis of hepatocellular carcinoma with portal vein tumor thrombus:assessment based on clinical and computer tomography characteristics[J]. Acta Med Okayama, 2012, 66(2): 131-141.
18
Zhao Y, Cai G, Zhou L, et al. Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review[J]. Asia Pac J Clin Oncol, 2013, 9(4): 357-364. doi: 10.1111/ajco.12081.
19
Kim KM, Kim JH, Park IS, et al. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion[J]. J Gastroenterol Hepatol, 2009, 24(5): 806-814. doi: 10.1111/j.1440-1746.2008.05728.x.
[1] 王杰, 袁泉, 王玥琦, 乔佳君, 谭春丽, 夏仲元, 刘守尧. 溃疡油在糖尿病足溃疡治疗中的应用效果及安全性观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 480-484.
[2] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[3] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[4] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[5] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[6] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[7] 刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[8] 焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[9] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[10] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[11] 吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[12] 陈杰, 武明胜, 李一金, 李虎, 向源楚, 荣新奇, 彭健. 低位直肠癌冷冻治疗临床初步分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 494-498.
[13] 史彬, 司远. 益气和络方联合缬沙坦治疗气阴两虚兼血瘀证IgA 肾病的疗效观察[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 306-312.
[14] 韩俊岭, 王刚, 马厉英, 连颖, 徐慧. 维生素D 联合匹维溴铵治疗腹泻型肠易激综合征患者疗效及对肠道屏障功能指标的影响研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 560-564.
[15] 阳跃, 庹晓晔, 崔子豪, 欧阳四民, 林海阳, 胡景宇, 胡银, 李涛, 赵景峰, 郝岱峰, 冯光. 改良“阅读者”皮瓣修复骶尾部压疮的疗效[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 751-755.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？